Vertex Pharmaceuticals reported that 10 out of 12 patients receiving its investigational off-the-shelf stem cell therapy for type 1 diabetes were able to discontinue insulin injections one year after treatment. The therapy, called zimislecel (previously VX-880), consists of lab-grown islet cells designed to restore insulin production. Trial data, presented at the American Diabetes Association conference and published in the New England Journal of Medicine, show sustained glucose control without severe hypoglycemia, marking a significant advance in cell therapy for insulin-dependent diabetes.